Hematologic Oncology Update
Featuring one-on-one interviews conducted by Dr Neil Love, this series provides medical oncologists with access to an array of important perspectives and information on relevant advances in the treatment of hematologic cancer to facilitate optimal patient care.
Latest episodes
Oct 12, 2023 • 46min
Oncology Today with Dr Neil Love: Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma with Dr Matthew Matasar
Dr Matthew Matasar from the Rutgers Cancer Institute of New Jersey in New York, New York, discusses the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma.
Oct 9, 2023 • 48min
What Clinicians Want to Know About Anti-CD38 Antibodies in the Management of Multiple Myeloma
Prof Philippe Moreau from the University Hospital of Nantes in France discusses anti-CD38 antibody-based treatment approaches for newly diagnosed and relapsed/refractory multiple myeloma, moderated by Dr Neil Love.
Oct 5, 2023 • 34min
Oncology Today with Dr Neil Love: Blastic Plasmacytoid Dendritic Cell Neoplasm
Dr Naveen Pemmaraju from the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses current and emerging management approaches for blastic plasmacytoid dendritic cell neoplasms.
Sep 28, 2023 • 39min
Oncology Today with Dr Neil Love: Emerging Role of CELMoDs (Cereblon E3 Ligase Modulators) and Other Novel Approaches to Targeting Protein Degradation Pathways in Multiple Myeloma
Dr Paul G Richardson from Dana-Farber Cancer Institute in Boston discusses the emerging role of CELMoDs and other novel approaches to targeting protein degradation pathways in the treatment of multiple myeloma.
Sep 22, 2023 • 1h 3min
What Clinicians Want to Know About Toxicity Considerations Associated with BTK Inhibitors
Dr Nicole Lamanna from the Columbia University Herbert Irving Comprehensive Cancer Center in New York, New York, and Dr William G Wierda from The University of Texas MD Anderson Cancer Center in Houston, Texas, discuss the spectrum of toxicities associated with BTK inhibitors and strategies for their mitigation and management for patients with chronic lymphocytic leukemia and mantle cell lymphoma.
Sep 14, 2023 • 1h 1min
Inside the Issue: The Current and Future Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma
Experts Dr Martin Hutchings and Dr Loretta Nastoupil discuss the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma. Topics include different agents, efficacy, tolerability, dose step up, treatment duration, challenges in generating order sets, patient experience, comparing immunotherapies, and side effect profiles.
Aug 31, 2023 • 43min
Oncology Today with Dr Neil Love: Role of BTK Inhibitors in Patients with Mantle Cell Lymphoma
Featuring a discussion on BTK inhibitors for the management of mantle cell lymphoma with Dr Michael Wang, moderated by Dr Neil Love.
Aug 30, 2023 • 1h 2min
Meet The Professor: Optimizing the Management of Soft Tissue Sarcoma and Related Connective Tissue Disorders — Part 2 of a 2-Part Series
Dr Richard F Riedel from Duke Cancer Institute in Durham, North Carolina, discusses approved and novel treatment approaches for soft tissue sarcoma, moderated by Dr Neil Love.
Aug 29, 2023 • 36min
Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Chronic Lymphocytic Leukemia and Lymphoma from Recent Major Oncology/Hematology Conferences
Dr Jeremy Abramson from Massachusetts General Hospital in Boston discusses key presentations on chronic lymphocytic leukemia and lymphomas from recent oncology/hematology conferences.
Aug 23, 2023 • 1h 1min
Inside the Issue: Integrating Bispecific Antibodies into the Management of Multiple Myeloma — Patient Selection and Toxicity Management
Dr Hans Lee from The University of Texas MD Anderson Cancer Center in Houston, Texas, and Dr Saad Zafar Usmani from Memorial Sloan Kettering Cancer Center in New York, New York, discuss approved and novel bispecific antibodies and their current and potential roles in the treatment of multiple myeloma.
